Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide in Asymptomatic or Stable Multiple Myeloma
NCT01094548Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2008
- Primary completion
- Feb 2011
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tecemotide in multiple myeloma (MM), sponsored by Merck KGaA. Started Jan 2008; status: completed.
02
Drugs
tecemotide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01094548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094548.